CJC-1295 No DAC / Ipamorelin Blend

This blend pairs the GHRH analogue CJC-1295 No DAC with the ghrelin-receptor agonist ipamorelin at 1:1, sold as 5/5 or 10/10 mg.

Community-reportedFixed-ratio blend reference

Also known as: ModGRF 1-29 / Ipamorelin

(how we review)

Open the calculator

Blend calculations, explained

A fixed-ratio blend requires component-aware arithmetic. Vial composition is kept separate from target amounts so component strengths are never presented as dose suggestions.

Per-component concentration math

Choose the exact vial variant. The Advanced Blend workspace prefills each component and calculates every component concentration from one shared prepared volume.

Vial strength is not a target amount

Each listed number identifies how much of one component is present in the full vial. It does not establish how much of the blend to draw or how often.

How to read the dosing on this page

Blend-level rows

Reported protocols describe how sources reconstitute and draw this vial as a whole, each tied to where it was said.

Component rows

Each peptide's own page reports what studies and guides describe for it alone; the leading rows are repeated below.

One draw, every component

The ratio is fixed by the vial, so a draw sized for one component sets the amount of all the others at the same time.

Molecular profile of each component

CJC-1295 No DAC / Ipamorelin Blend is 2 peptides in one vial. Each profile below is PubChem's record for that peptide, read from its own library page; the vial amount is what the label states for this blend, not an amount per draw.

CJC-1295 No DAC5 mg in the 5 / 5 mg vial; 10 mg in the 10 / 10 mg vial

Formula
C152H252N44O42
Molar mass
3,367.9 g/mol
CAS number
863288-34-0
Amino acids
29
Sequence
Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2
Class
Synthetic GHRH(1-29) amide with four substitutions (D-Ala2, Gln8, Ala15, Leu27). PubChem's synonym list for this record mixes DAC and no-DAC names, but the drawn structure and 3367.9 g/mol mass are the peptide without the maleimidopropionyl linker; CJC-1295 with DAC is a separate record (CID 91971820, 3647.2 g/mol)

PubChem CID 56841945CJC-1295 No DAC page

Ipamorelin5 mg in the 5 / 5 mg vial; 10 mg in the 10 / 10 mg vial

Formula
C38H49N9O5
Molar mass
711.9 g/mol
CAS number
170851-70-4
Amino acids
5
Sequence
Aib-His-D-2-Nal-D-Phe-Lys-NH2
Class
Synthetic pentapeptide ghrelin receptor (GHS-R1a) agonist; selective growth hormone secretagogue

PubChem CID 9831659Ipamorelin page

Reported protocols for CJC-1295 No DAC / Ipamorelin Blend

What published studies and recent community write-ups report about amounts, timing and course length. 1 clinical and 3 community-reported rows, each linked to its source. These are descriptions of what others report, not instructions, and nothing here is medical advice.

ContextDoseFrequencyRouteCourseSource
Clinical1 row
Related combination (not this product): GHRH plus GHRP-6 in healthy men18 healthy menGHRP-6 0.1, 0.3 or 1.0 mcg/kg; GHRH(1-44) 1.0 mcg/kg alone or together with GHRP-6Single intravenous bolus per testIntravenousSingle administrationsNot applicableJournal of Clinical Endocrinology and Metabolism (PubMed)1990
The study that established GHRH plus GHRP synergy in people, included here as a related combination rather than a test of the blend. Peak GH after placebo and 0.1, 0.3 and 1.0 mcg/kg GHRP-6 was 1.2, 7.6, 16.5 and 68.7 mcg/L, and the two submaximal GHRP-6 doses given with 1 mcg/kg GHRH released more GH than the sum of the parts; prolactin and cortisol roughly doubled only at the top GHRP-6 dose. Different GHRP, different GHRH, intravenous route, single doses: this is the mechanistic basis for pairing a GHRH analogue with a GHRP, not evidence for CJC-1295 No DAC with ipamorelin.
Community-reported3 rows
Community guide: 5/5 mg vial in 3 mL, titrated once daily100 mcg of each peptide (3 units) in weeks 1-2, 150 mcg (4.5 units) in weeks 3-4, 200 mcg (6 units) in weeks 5-6, 250-300 mcg (7.5-9 units) in weeks 7-12Once dailySubcutaneous, before bed or on waking; sites rotated8-12 weeks, optionally extended to 16Not described beyond ending the courseCommunity resource2026
Reconstitutes the 10 mg (5 + 5) vial with 3.0 mL of bacteriostatic water for 3.33 mg/mL in total, so 1 unit on a U-100 syringe carries about 33 mcg of each peptide; the small draws are why it suggests 30- or 50-unit syringes. It counts 3 vials for 8 weeks and 4 for 12. The same table appears almost word for word on several vendor help pages, so it is one template rather than independent corroboration. Published March 2026, updated September 2026.
Practitioner site: monitoring-centred protocol100 mcg of each to start; 100-300 mcg of each per injectionOnce daily at bedtime, escalated by some to 2-3 injections a day (morning, pre-workout, bedtime)Subcutaneous, in the same syringe or as sequential injections8-16 weeks on4-8 weeks off; IGF-1 rechecked before each new cycleCommunity resource2025
A telehealth site's protocol built around laboratory monitoring: baseline IGF-1, fasting glucose, HbA1c and lipids, IGF-1 repeated at week 8 with a 50% dose cut if it exceeds the age-adjusted range, and a metabolic panel at week 12. It states plainly that no randomized trial has tested the pair, that the cycle length has no trial basis, and that people over 60 should start at 100 mcg of each once nightly with IGF-1 checked at 6 weeks. Reviewed July 2025.
Community guide: saturation doses and fasted timing100-200 mcg CJC-1295 No DAC with 100-300 mcg ipamorelin per injection1-3 times daily, fasted (60-90 minutes after a meal), often before sleepSubcutaneous, abdomen or thigh8-16 weeks in most reported protocolsWashout between courses; length not specifiedCommunity resource2026
Argues that both peptides saturate pituitary receptors at roughly 100 mcg per injection, so larger doses extend rather than enlarge the GH pulse, and that glucose and insulin blunt the response, hence fasted and pre-sleep timing. For a 5/5 blend vial it describes 2 mL of bacteriostatic water (1 mg/mL of each peptide) and 28 days refrigerated, and it states that no human RCT has tested the combination at these doses. Note that its separate ranges for the two peptides cannot be followed from a 1:1 vial, where every draw delivers equal micrograms of each. Published July 2026.

How a course is commonly described

  1. Weeks 1-2Community-reported

    The common template starts at 100 mcg of each peptide once daily, 3 units of a 5/5 vial made up with 3 mL, injected subcutaneously before bed or on waking.

  2. Weeks 3-6Community-reported

    The same template steps up by about 50 mcg of each every one to two weeks: 150 mcg (4.5 units) in weeks 3-4 and 200 mcg (6 units) in weeks 5-6.

  3. Weeks 7-12 and the week 8 checkCommunity-reported

    Doses plateau at 250-300 mcg of each. The practitioner protocol repeats IGF-1 at week 8, halves the dose if it is above the age-adjusted range, and adds fasting glucose and HbA1c at week 12.

  4. BreakCommunity-reported

    Courses run 8-16 weeks with a 4-8 week break described, justified by receptor recovery and a fresh IGF-1 baseline rather than by any trial of the pair.

  5. Clinical comparisonClinical

    The only human synergy data are single intravenous boluses of GHRH with GHRP-6 measured over an hour; no human study has followed a multi-week GHRH plus GHRP course, let alone this blend.

  • No published trial, observational study or registered study has given CJC-1295 and ipamorelin together to people. The synergy argument rests on GHRH plus GHRP-6 work from 1990 and the later diagnostic GHRH-GHRP-6 test, and the only human CJC-1295 trials used the albumin-binding DAC molecule, which lasts about a week and is not what daily blend vials contain.
  • The vial fixes the ratio at 1:1, so a draw that delivers 200 mcg of ipamorelin also delivers 200 mcg of CJC-1295 No DAC. Guides that give the two peptides different ranges are describing separate vials; with the blend the two numbers are always equal, and the 5/5 and 10/10 vials differ only in concentration for a given water volume.
  • CJC-1295 No DAC is modified GRF 1-29, a short-acting peptide cleared in well under an hour, which is why the blend is dosed daily or several times a day. The vendor sells only the 5/5 vial, and an independent May 2026 Chromate test of a shop-provided vial found 9.932 mg against the 10 mg label at 99.56% purity, with no sterility or heavy-metal screen.
  • Neither peptide is approved anywhere. In 2024 the FDA's compounding advisory committee voted 12-0 against ipamorelin and 13-0 against CJC-1295 for the 503A bulks list, and both are prohibited at all times by WADA under S2.2.4. The practitioner protocol's IGF-1 and glucose monitoring reflects the known effects of raising GH; none of the rows above is an endorsement of use.
Sources for this section (7)
  1. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormoneJournal of Clinical Endocrinology and Metabolism (PubMed)1990Clinical

Plus 6 community resources (dosing guides, forum threads and vendor write-ups), reported above but not linked.

Reported protocols by component

What sources report for each peptide on its own. In CJC-1295 No DAC / Ipamorelin Blend the vial ratio fixes the proportions, so one draw delivers every component at once and none can be raised without the others. The first rows from each component's table are shown here; its page carries the rest, each linked to its source. Descriptions of what others report, not instructions.

CJC-1295 No DAC

  • ClinicalCJC-1295 with DAC, ascending single and repeated doses (not the no-DAC peptide)
    Reported amount
    Four ascending single doses, with 30 and 60 mcg/kg described as the best tolerated
    Frequency
    Single injection, or two to three injections weekly or every two weeks
    Route
    Subcutaneous
    Course
    28 days (single-dose study) and 49 days (repeat-dose study)
    Journal of Clinical Endocrinology and Metabolism (PubMed), 2006
  • Community-reportedCommunity saturation-dose protocol with a GHRP
    Reported amount
    100 mcg (about 1 mcg/kg) per injection, paired with 100 mcg ipamorelin
    Frequency
    1-3 times daily, fasted; bedtime dose described as the most important
    Route
    Subcutaneous
    Course
    3-6 months or longer described as tolerated
    Community resource, 2026
  • ClinicalCJC-1295 with DAC, overnight GH pulsatility study (not the no-DAC peptide)
    Reported amount
    60 or 90 mcg/kg
    Frequency
    Single injection, sampled every 20 minutes overnight before and one week after
    Route
    Subcutaneous
    Course
    One week
    Journal of Clinical Endocrinology and Metabolism (PubMed), 2006
3 more rows on the CJC-1295 No DAC page

Ipamorelin

  • ClinicalIntravenous dose-escalation pharmacokinetic study
    Reported amount
    4.21, 14.02, 42.13, 84.27 or 140.45 nmol/kg (roughly 3-100 mcg/kg)
    Frequency
    Single 15-minute infusion
    Route
    Intravenous
    Course
    Single administration
    Pharmaceutical Research (Springer), 1999
  • Community-reportedCompounding-pharmacy protocol summary
    Reported amount
    200-300 mcg (new users 100-150 mcg; some protocols up to 400-500 mcg)
    Frequency
    Once daily at bedtime; advanced protocols add a fasted morning or pre-workout dose
    Route
    Subcutaneous
    Course
    3-6 months
    Community resource, 2026
  • PreclinicalDiscovery pharmacology in rats and pigs
    Reported amount
    ED50 80 nmol/kg in rats and 2.3 nmol/kg in pigs for GH release; selectivity held at more than 200 times the ED50
    Frequency
    Single doses
    Route
    Intravenous
    Course
    Single administration
    European Journal of Endocrinology (PubMed), 1998
6 more rows on the Ipamorelin page

What is available now

These fields come from the existing picker, blend catalog and observed presentation data. They are identity and availability context, not evidence of effectiveness.

This blend pairs the GHRH analogue CJC-1295 No DAC with the ghrelin-receptor agonist ipamorelin at 1:1, sold as 5/5 or 10/10 mg. It is the classic GHRH plus GHRP stack, sold by the vendor and many other vendors and marketed for growth hormone release, sleep, recovery and body composition; community guides describe 100-300 mcg of each peptide once to three times daily, fasted or at bedtime, in 8-16 week courses. No trial has tested this product or these two peptides together: the human synergy evidence comes from 1990 studies of GHRH given with the older GHRP-6, and every human CJC-1295 trial used the long-acting DAC form, so the component pages carry the evidence.

  • 1

    Entry type

    Fixed-ratio blend reference

    Kept separate from single-peptide evidence and terminology.

  • 2

    Evidence status

    Structured review queued

    No evidence level is assigned until references and study models are reviewed.

  • 3

    Calculator access

    Advanced Blend workspace

    Calculator access performs arithmetic; it does not establish an amount or protocol.

  • 4

    Market presentation data

    No reviewed observation on file

    The vial label remains the authoritative source for any calculation.

Recorded blend variants

Each number is the vial amount for that component. It is not a per-draw amount.

5 / 5 mg
CJC-1295 No DAC
5 mg
Ipamorelin
5 mg
10 / 10 mg
CJC-1295 No DAC
10 mg
Ipamorelin
10 mg

Sources

3 curated references, each with its journal, year and study model, plus 6 community resources reported but not linked.

  1. Modified GRF (1-29), CJC-1295 without DAC (PubChem CID 56841945)PubChem, National Library of Medicine2026Not graded
  2. Ipamorelin (PubChem CID 9831659)PubChem, National Library of Medicine2026Not graded
  3. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormoneJournal of Clinical Endocrinology and Metabolism (PubMed)1990Human

Guides that go deeper